Antibodies to cyclin E2 protein

Details Antibodies to cyclin E2 protein Antibodies to cyclin E2 protein

2005-09-13

2005-09-13

Murphy, Joseph (Department: 1646)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Blood proteins or globulins, e.g., proteoglycans, platelet...

C530S387900, C530S387100, C530S387200, C435S007100

Reexamination Certificate

active

06943238

ABSTRACT:
Disclosed are nucleic acid molecules encoding novel cyclin E2 polypeptides. Also disclosed are methods of preparing the nucleic acid molecules and polypeptides, and methods of using these molecules.

REFERENCES:
patent: 3773919 (1973-11-01), Boswell et al.
patent: 4892538 (1990-01-01), Aebischer et al.
patent: 4970154 (1990-11-01), Chang
patent: 5011472 (1991-04-01), Aebischer et al.
patent: 5106627 (1992-04-01), Aebischer et al.
patent: 5252714 (1993-10-01), Harris et al.
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5449755 (1995-09-01), Roberts et al.
patent: 5489743 (1996-02-01), Robinson et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5557032 (1996-09-01), Mak
patent: 5593875 (1997-01-01), Wurm et al.
patent: 5631236 (1997-05-01), Woo et al.
patent: 5635399 (1997-06-01), Kriegler et al.
patent: 5645999 (1997-07-01), Roberts et al.
patent: 5653975 (1997-08-01), Baetge et al.
patent: 5672344 (1997-09-01), Kelly et al.
patent: 5676954 (1997-10-01), Brigham
patent: 5679559 (1997-10-01), Kim et al.
patent: 5688665 (1997-11-01), Massague et al.
patent: 0 036 676 (1979-03-01), None
patent: 0 038 481 (1981-04-01), None
patent: 0 088 046 (1983-02-01), None
patent: 0 143 949 (1984-10-01), None
patent: 0 133 988 (1985-03-01), None
patent: 0 154 316 (1985-03-01), None
patent: 0 401 384 (1989-12-01), None
patent: WO 91/10425 (1991-07-01), None
patent: WO 93/06123 (1993-04-01), None
patent: WO 94/28122 (1994-12-01), None
patent: WO 96/02140 (1996-02-01), None
patent: WO 96/40958 (1996-12-01), None
patent: WO9709341 (1997-03-01), None
patent: WO 98/03649 (1998-01-01), None
Mickle JE et al. Genotype-phenotype relationships in cystic fibrosis. Med Clin North Am. May 2000;84(3):597-607.
Voet et al. Biochemistry. 1990. John Wiley & Sons, Inc. pp. 126-128 and 228-234.
Yan et al., Two-amino acid molecular switch in an epithelial morphogen that regulates binding to two distinct receptors. Science 290: 523-527, 2000.
Hillier L., et al.,The WashU-Merck EST Project,Genbank Accession No. R84331, Jan. 22, 1999.
Cyclins, Prosite Accession No. PS00292, Created Apr. 1990, Updated Nov. 1995, and Information Update, Feb. 2005.
Ausubel et al., eds.,Current Protocols in Molecular Biology,Green Publishers Inc. and Wiley Sons, NY (1994) (Table of Contents Provided).
Ausubel et al., eds., “Metal-Chelate Affinity Chromatography”,Current Protocols in Molecular Biology,Section 10.11.8, John Wiley & Sons, NY (1993).
Chevalier et al., “Xenopus cyclin E, a nuclear phosphoprotein, accumulates when oocytes gain the ability to initiate DNA replication”,J. Cell Sci., 109: 1173-1184 (1996).
Coats et al., “23 Cell cycle regulation”,Signal Transduction,Heldin and Purton, eds., Chapman and Hall, publishers, 347-360 (1996).
Cook, “Scintillation proximity assay: a versatile high-throughput screening technology”,Drug Discovery Today, 1: 287-294 (1996).
Damjanov et al., “Molecular Cloning and Characterization of Murine Cyclin E#”,Biochem. Biophys. Res. Comm., 201: 994-1000 (1994).
Dayhoff et al.,Atlas of Protein Sequence and Structure, 5, supp. 3 (1978) (Table of Contents Provided).
Diehl et al., “A Dominant-Negative Cyclin D1 Mutant Prevents Nuclear Import of Cyclin-Dependent Kinase 4 (CDK$) and Its Phosphorylation by CDK-Activating Kinase”,Mol. Cell. Biol., 17: 62-7374 (1997).
Engels et al., “Gene Synthesis”,Angew. Chem. Intl. Ed., 28: 716-734 (1989).
Eppstein et al., “Biological activity of liposome-encapsulated murine interferon y is mediated by a cell membrane receptor”,Proc. Natl. Acad. Sci. USA, 82: 3688-3692 (1985).
Francis, “Protein modification and fusion proteins”,Focus on Growth Factors, 3: 4-10 (1992).
Gennaro, ed.,Remington's Pharmaceutical Sciences,18thEdition, Mack Publishing Company (1990) (Table of Contents Provided).
Gray-Bablin et al., “Cyclin E, a redundant cyclin in breast cancer”,Proc. Natl. Acad. Sci USA, 93: 15215-15220 (1996).
Gudas et al., “Nuclear posttranscriptional processing of thymidine kinase mRNA at the onset of DNA synthesis”,Proc. Natl. Acad. Sci. USA, 85: 4705-4709 (1988).
Harlow et al., eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY p. 49 (1998).
Houghten et al., “General method for the rapid solid-phase synthesis of large numbers of peptides: Specificity of antigen-antibody interaction at the level of individual amino acids”,Proc Natl Acad. Sci. USA, 82: 5132 (1985).
Kitts et al., “A Method for Producing Recombinant Baculovirus Expression Vectors at High Frequency”,Biotechniques, 14: 810-817 (1993).
Koff et al., “Human Cyclin E, a New Cyclin That Interacts with Two Members of the CDC2 Gene Family”,Cell, 66: 1217-1228 (1991).
Langer et al., “Biocompatibility of polymeric delivery systems for macromolecules”,J. Biomed. Mater. Res., 15: 167-277 (1981).
Langer, “Controlled release of macromolecules”,Chem. Tech., 12; 98-105 (1982).
Lauper et al., “A New G1-Specific Cyclin in Mammalian Cells”,Abstracts from the 1998 Cold Spring Harbor Laboratory Cell Cycle Meeting,Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, p. 115 (1998).
Lees, “Cyclin dependent kinase regulation”,Curr. Opinions Cell Biol., 7: 773-780 (1995).
Lucklow et al., “Efficient Generation of Infectious Recombinant Baculoviruses by Site-Specific Transposon-Mediated Insertion of Foreign Genes into a Baculovirus Genome Propagated inEscherichia coli”, J. Virol., 67: 4566-4579 (1993).
Lucklow, “Baculovirus systems for the expression of human gene products”,Curr. Opin. Biotechnol., 4: 564-572 (1993).
Marston et al., “Solubilization of Protein Aggregates”,Meth. Enz., 182: 264-275 (1990).
Merrifield et al., “Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide”,J. Am. Chem. Soc., 85: 2149 (1963).
Mumberg et al., “Cyclin E, a new splice variant of human cyclin E with a unique expression pattern during cell cycle progression and differentiation”,Nuc. Acids Res., 25: 2098-2105 (1997).
Ninomiya-Tsuji et al., “Cloning of a human cDNA encoding a CDC2-related kinase by complementation of a budding yeast cdc28 mutation”,Proc. Natl. Acad. Sci. USA, 88: 9006-9010 (1991).
O'Reilly et al., “Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth”,Cell, 88: 277-285 (1997).
Ohtsubo et al., “Human Cyclin E, a Nuclear Protein Essential for the G1-to-S Phase Transition”,Mol. Cell. Biol., 15: 2612-2624 (1995).
Polyak et al., “Cloning of p27Kp1, a Cyclin-Dependent Kinase Inhibitor and a Potential Mediator of Extracellular Antimitogenic Signals”,Cells, 78: 59-66 (1994).
Porter et al., “Expression of cell-cycle regulators p27Kp1and cyclin E, alone and in combination, correlate with survival in young breast cancer patients”,Nature Med., 3: 222-225 (1997).
Richardson et al., “A Drosophila G1-specific cyclin E homolog exhibits different modes of expression during embryogenesis”,Development, 119: 673-690 (1993).
Sambrook et al.,Molecular Cloning: A Laboratory Manual,Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1989) (Table of Contents Provided).
Sarcevic et al., “Differential Phosphorylation of T-47D Human Breast Cancer Cell Substrates by D1-, E-, and A-type Cyclin-CDK Complexes*”,J. Biol. Chem., 272: 33327-33337 (1997).
Sheaff et al., “Cyclin E-CDK2 is a regulator of p27Kp1”,Genes and Devel., 11: 1464-1478 (1997).
Sherr et al., “Inhibitors of mammalian G1cyclin-dependent kinases”,Genes and Devel., 9: 1149-1163 (1995).
Sherr, “Cancer Cell Cycles”,Science, 274: 1672-1677 (1996).
Sidman et al., “Controlled Release of Macromolecules and Pharmaceuticals from Synthetic Polypeptides Based on Glutamic Acid”,Biopolymers, 22: 547-556 (1983).
Stewart and Young, Solid Phase Peptide Synthesis, Pierce Chemical

Affiliated with

Also associated with

Rating

Antibodies to cyclin E2 protein does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibodies to cyclin E2 protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to cyclin E2 protein will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3413399